LAUSR

Type 1 diabetes (T1D) is a wide heterogeneous disease in terms of age at onset, insulin secretory capacity (mirrored by the residual β-cell function) and complication/progression rates. Different T1D patient endotypes have been identified paving the way for therapeutic efforts to preserve or rescue β-cell function. In this commentary we highlight the relevance of defining endotypes for immune intervention strategies in T1D. This article is protected by copyright. All rights reserved.